NCT06656494View on ClinicalTrials.gov

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

January 31, 2028

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)
Interventions
DRUG

ICP-248

Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle

DRUG

Azacitidine

Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol，once daily on days 1-7 of each 28-day cycle.

Trial Locations (6)

100044

RECRUITING

Peking University People's Hospital, Beijing

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

300192

RECRUITING

Tianjin People's Hospital, Tianjin

310012

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

330006

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY